ArticleJournal of gastroenterology2010
CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma.
Article in Journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.Molecular neurobiology · 2016Pooled it
- Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review.PloS one · 2013Pooled it
- Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance.Frontiers in immunology · 2026Review
- Review
- Article
- Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells.Cancer communications (London, England) · 2021Review
- Cancer Stem Cells in Intrahepatic Cholangiocarcinoma; Their Molecular Basis, and Therapeutic Implications.Frontiers in physiology · 2021Review
- Review
- Targeting cancer stem cells in cholangiocarcinoma (Review).International journal of oncology · 2020Review
- Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.International journal of molecular sciences · 2019Review
- Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer.Oncology letters · 2018Article
- CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma.Journal of translational medicine · 2018Article
- Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of sonic hedgehog signaling.Oncology letters · 2018Article
- Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma.International journal of molecular sciences · 2017Review
- Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma.Oncology letters · 2015Article
- Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma.International journal of clinical and experimental pathology · 2015Article
- The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review).International journal of oncology · 2014Review
- Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2014Article
- High expression of cancer stem cell markers in cholangiolocellular carcinoma.Surgery today · 2013Article
- Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.Surgery today · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimCD133 is one of the most important cancer-initiating (stem) cell markers and was confirmed to be expressed in solid cancers such as colon cancer. However, no one has investigated the role of CD133 in intrahepatic cholangiocarcinoma (IHCC). The aim of this study was to clarify the clinical role of CD133 expression in IHCC. PATIENTS AND
methodsTwenty-nine patients with IHCC who underwent hepatic resection at our institution were enrolled in this study. Expression of CD133 was examined using anti-CD133 antibody. Staining was observed in the cytoplasm of cancer cells and CD133-positive cells distributed in the whole tumor. The patients were divided into two groups: the CD133-positive group (n = 14) and CD133-negative group (n = 15), in which no staining of CD133 was observed. Clinicopathological factors including hypoxia-inducible factor-1alpha expression were compared between the two groups. The prognostic factors were investigated by multivariate analysis using Cox's proportional hazard model.
resultsThe 5-year survival rate in the CD133-positive group (8.0%) was worse than that in the CD133-negative group (57.0%). In the CD133-positive group, the incidence of intrahepatic metastasis and positive expression of hypoxia-inducible factor-1alpha tended to be higher than that in the CD133 negative group. The multivariate analysis revealed CD133 expression was an independent prognostic indicator in IHCC.
conclusionsCD133 expression tended to be related to higher incidences of intrahepatic metastasis and positive expression of hypoxia-inducible factor-1alpha; furthermore, it was independently related to worse prognosis. Therefore, the CD133 expression is a potential prognostic indicator in IHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.